Liquidia Corporation

Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of the company's proprietary PRINT? technology to transform the lives of patients. The company is focused on the development of two product candidates for which it holds commercial rights: LIQ861, which is for the treatment of pulmonary arterial hypertension, a disease caused by the hardening and narrowing of the pulmonary arteries that can lead to right heart failure and eventually death; and LIQ865, which is an injectable, sustained-release formulation of bupivacaine for the management of local post-operative pain a surgical procedure.
  • TickerLQDA
  • ISINUS53635D2027
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 14 2021 6:52AM

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

Wedbush PacGrow Healthcare Conference

Wedbush Research

Wedbush Morning Call - Jun 07 2021 6:57AM

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

The Week Ahead in Life Sciences

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 14 2021 6:52AM

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

Wedbush PacGrow Healthcare Conference

Wedbush Research

Wedbush Morning Call - Jun 07 2021 6:57AM

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

The Week Ahead in Life Sciences

ResearchPool Subscriptions

Get the most out of your insights

Get in touch